Andrew Lo Acquires 18,204 Shares of Urovant Sciences Ltd (NASDAQ:UROV) Stock

Share on StockTwits

Urovant Sciences Ltd (NASDAQ:UROV) major shareholder Andrew Lo purchased 18,204 shares of the business’s stock in a transaction dated Wednesday, June 19th. The stock was bought at an average price of $8.32 per share, with a total value of $151,457.28. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Andrew Lo also recently made the following trade(s):

  • On Monday, June 3rd, Andrew Lo purchased 17,746 shares of Urovant Sciences stock. The stock was bought at an average price of $7.83 per share, with a total value of $138,951.18.
  • On Thursday, May 23rd, Andrew Lo purchased 19,830 shares of Urovant Sciences stock. The stock was bought at an average price of $8.22 per share, with a total value of $163,002.60.

NASDAQ:UROV traded up $0.21 during mid-day trading on Wednesday, hitting $8.19. 52,700 shares of the company’s stock traded hands, compared to its average volume of 61,217. The company has a current ratio of 8.34, a quick ratio of 11.00 and a debt-to-equity ratio of 0.18. Urovant Sciences Ltd has a 1 year low of $4.05 and a 1 year high of $14.49. The company has a market capitalization of $247.19 million and a P/E ratio of -1.85.

Urovant Sciences (NASDAQ:UROV) last posted its earnings results on Thursday, June 13th. The company reported ($0.96) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.96). On average, equities research analysts predict that Urovant Sciences Ltd will post -4.18 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Weiss Multi Strategy Advisers LLC increased its holdings in Urovant Sciences by 38.2% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after acquiring an additional 4,146 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in Urovant Sciences during the 1st quarter valued at about $49,000. Barclays PLC purchased a new position in Urovant Sciences during the 4th quarter valued at about $37,000. Two Sigma Investments LP purchased a new position in Urovant Sciences during the 4th quarter valued at about $72,000. Finally, Marshall Wace LLP purchased a new position in Urovant Sciences during the 1st quarter valued at about $325,000. Hedge funds and other institutional investors own 21.93% of the company’s stock.

A number of equities analysts have recently issued reports on UROV shares. SunTrust Banks started coverage on shares of Urovant Sciences in a report on Friday, March 15th. They issued a “buy” rating and a $24.00 price target for the company. HC Wainwright started coverage on shares of Urovant Sciences in a report on Monday, March 11th. They issued a “buy” rating and a $28.00 price target for the company. Zacks Investment Research upgraded shares of Urovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 21st. Finally, JPMorgan Chase & Co. set a $24.00 price target on shares of Urovant Sciences and gave the company a “buy” rating in a report on Friday, June 14th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $21.63.

TRADEMARK VIOLATION WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/4379914/andrew-lo-acquires-18204-shares-of-urovant-sciences-ltd-nasdaqurov-stock.html.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Recommended Story: Tariff

Insider Buying and Selling by Quarter for Urovant Sciences (NASDAQ:UROV)

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report